Book.
0000 - Gale Group | MOMW2
Vikram Premkumar, Suzanne Lentzsch, Samuel Pan, Divaya Bhutani, Joshua Richter, Sundar Jagannath, Michaela Liedtke, Arnaud Jaccard, Ashutosh D. Wechalekar, Raymond L. Comenzo, Vaishali Sanchorawala, Bruno Royer, Michael Rosenzweig, Jason Valent, Stefan Schönland, Rafaël Fonseca, Sandy W. Wong, Prashant Kapoor,
Abstract Venetoclax is efficacious in relapsed/refractory t(11;14) multiple myeloma, thus warranting investigation in light-chain ... US and Europe. Thirty-one patients harbored t(11;14), 11 did not, and one t(11;14) status was unknown. Patients received a venetoclax-containing ... patients was 68%; 63% achieved VGPR/CR. t(11;14) patients had higher hematologic response (81% vs. 40%) ... CI 0.02–0.62) than non-t(11;14) patients. For the unsegregated cohort, median progression-free ... median OS was not reached (NR). For t(11;14), median PFS was NR and for non-t( ...
Tópico(s): Myeloproliferative Neoplasms: Diagnosis and Treatment
2021 - Springer Nature | Blood Cancer Journal
... Nouveaux Exercises e Mathématique (Exercises de Prague)--T. 11-14. Exercices D'analyse et de Physique Mathématique... [2. ...
1899 - Gale Group | NCCO SciTechMed 2 of 2
Gonzalo Hernández, Francisco Javier Ramos, José M. Añón, Ramón Ortiz, Laura Colinas, Joan Ramón Masclans, Candelaria de Haro, Alfonso Ortega, Óscar Peñuelas, María del Mar Cruz-Delgado, Alfonso Canabal Berlanga, Oriol Plans, Concepción Vaquero, Gemma Rialp, Federico Gordo, Amanda Lesmes González de Aledo, María Martínez-Martínez, Juan Carlos Figueira, Alejandro Gomez-Carranza, Rocio Corrales, Andrea Castellví, Beatriz Castiñeiras, Fernando Frutos‐Vivar, Jorge Prada, Raúl de Pablo, Antonio Naharro, Juan Carlos Montejo, Claudia Díaz, Alfonso Santos-Peral, Rebeca Padilla, Judith Marín‐Corral, Carmen Rodríguez-Solis, Juan Antonio Sánchez Giralt, Jorge Jiménez, Rafael Cuena, Santiago Pérez‐Hoyos, Oriol Roca,
... different timings (≤ 7 days, 8-10 days, and 11-14 days after intubation).ResultsOf 1,939 patients admitted ... days; 95% CI, 1.7-4.5 days; 11-14 days vs > 14 days [318 patients analyzed]: 4 ... different timings (≤ 7 days, 8-10 days, and 11-14 days after intubation). Of 1,939 patients admitted ... days; 95% CI, 1.7-4.5 days; 11-14 days vs > 14 days [318 patients analyzed]: 4 ... different timeframes (< 7 days, 8-10 days, or 11-14 days after intubation) within the entire cohort (unmatched ... after intubation (≤ 7 days, 8-10 days, and 11-14 days). e-Appendix 1 presents detailed information about ...
Tópico(s): Respiratory Support and Mechanisms
2021 - Elsevier BV | CHEST Journal
Grace Wyndham Goldie, H. G., C. H. Middleton, C. H. C. Cansdale, Moira Newman, C. J. S. Sprigge, T. Maskell Hardy, B. G. D. Salt, Alan Frank, A. R. Pargeter, Dorothy Thompson, J. C. Lewis Jones, Jaya Deva, Desmond MacCarthy, W. G. Freeman, H. E. Davis, Martin Armstrong, Gibbon Haydon, M. Nagib, Howard Hannay, Dr. Thomas Wood, J. H. Hall, George Berrie, Laurence Whistler, Helen Simpson, H. S. Ede, C. H. M., M. D. Calvocoressi,
... Quaint Old School Songs Radio News-Reel April 11-14 A pictorial summary of the week's news ...
1938 - Gale Group | The Listener GDA
Hareth Nahi, Muhammad Kashif, Monika Klimkowska, Maria Karvouni, Ann Wallblom, Charlotte Gran, Julia Hauenstein, Nicolai Frengen, Charlotte Gustafsson, Gabriel Afram, Katarina Uttervall, Johan Lund, Robert Månsson, Arnika Kathleen Wagner, Evren Alici,
... newly diagnosed multiple myeloma (NDMM) patients harbor t(11;14), a marker of inferior prognosis, resulting in up‐ ... to BCL2 inhibitor experimental drug venetoclax. Furthermore, t(11;14) is reported to be associated with increased BCL2/ ... myeloma (MM) and AL‐amyloidosis patients harboring t(11;14) and assessed safety and efficacy. Efficacy was assessed ... from venetoclax non‐treated group including non‐t(11;14) diagnosis (n = 27), t(11;14) diagnosis (n = 17), t(11;14) relapse (n = 7), hyperdiploidy (n = 6) and hyperdiploidy + ...
Tópico(s): Amyloidosis: Diagnosis, Treatment, Outcomes
2021 - Wiley | American Journal of Hematology
Errors in paging: 11-14 numbered 13, 14, 11, 12. Published anonymously. Spine title: Party tyranny in Carolina. Book.
0000 - Gale Group | Sabin
Susan Bal, Smith Giri, Kelly Godby, Luciano J. Costa,
... disease progression and relapse.1 MM harbouring t(11;14) has several additional unique features such as lymphoplasmacytoid morphology and expression of CD20.2 Further, t(11;14) may be a predictive biomarker as these patients ... inhibitor venetoclax.3 The prognostic significance of t(11;14) MM remains debatable. A better delineation of the natural history and prognosis of t(11;14) MM and understanding its behaviour in the presence ... variable of interest was the presence of t(11;14) by fluorescence in situ hybridization (FISH). We created ...
Tópico(s): Protein Degradation and Inhibitors
2021 - Wiley | British Journal of Haematology
... Nouveaux Exercises e Mathématique (Exercises de Prague)--T. 11-14. Exercices D'analyse et de Physique Mathématique... [2. ...
1892 - Gale Group | NCCO SciTechMed 2 of 2
Cristina Gasparetto, Sundar Jagannath, Robert M. Rifkin, Brian G.M. Durie, Mohit Narang, Howard R. Terebelo, Kathleen Toomey, James W. Hardin, Lynne I. Wagner, Sikander Ailawadhi, James Omel, Shankar Srinivasan, Mazaher Dhalla, Donna Catamero, Amani Kitali, Amit Agarwal, Rafat Abonour,
BackgroundThe t (11;14) (q13;32) translocation [t (11;14)] is present in ∼20% of patients with newly diagnosed multiple myeloma (NDMM), ... were used to examine the effect of t (11;14) status on first-line therapy outcomes in the ... with (n = 378) and without (n = 1196) t (11;14). Prevalence of t (11;14) was similar by race (AA, 27%; NAA, 24%). ... overall population, regardless of first-line therapy, t (11;14) status did not affect progression-free survival (hazard ... 0.99; P = .9417). AA patients with t (11;14) had higher likelihood of death (Nominal Cox regression ...
Tópico(s): Protein Degradation and Inhibitors
2021 - Elsevier BV | Clinical Lymphoma Myeloma & Leukemia
... Nouveaux Exercises E Mathématique (Exercises de Prague)--T. 11-14. Exercices D'analyse et de Physique Mathématique... [2. ...
1899 - Gale Group | NCCO SciTechMed 2 of 2
Clémentine Boccon‐Gibod, Alexis Talbot, Fabien Le Bras, Laurent Frenzel, Bruno Royer, Stéphanie Harel, Naëlle Lombion, Karim Belhadj, Wendy Cuccuini, Bertrand Arnulf,
... has mostly shown efficacy in patients harbouring t(11;14). Indeed, in a phase 1 clinical trial evaluating ... Relapsed/Refractory Multiple Myeloma) patients, the 45% t(11;14)-positive patients reached an overall response rate (ORR) of 40%, strongly contrasting with the remaining t(11;14)-negative patients for whom no more than 6% ... combination with PIs and dexamethasone even in t(11;14)-negative patients (Touzeau et al., 2018). Encouragingly, a ... of 67% that did not differ between t(11;14)-positive and negative patients (Moreau et al., 2017). ...
Tópico(s): Peptidase Inhibition and Analysis
2020 - Wiley | British Journal of Haematology
Astley's Amphitheatre, London Amphitheatre, London, Unspecified, Subject Amphitheatre, London, Unspecified, Subject,
... Office' (ff. 9 – 10); 'High Hill Ferry' (ff. 11 – 14); and, 'Toy Shop and Hairdressers' (ff. 15 – 17). ...
0000 - Gale Group | NCCO British Theatre
Kathryn T. Maples, Ajay K. Nooka, Vikas A. Gupta, Nisha S. Joseph, Leonard T. Heffner, Craig C. Hofmeister, Madhav V. Dhodapkar, Shannon M. Matulis, Sagar Lonial, Lawrence Boise, Jonathan L. Kaufman,
... in RRMM patients with the cytogenetic abnormality t(11;14). So, BCL2, an anti-apoptotic protein, is critical ... data confirmed MM samples positive for the t(11;14) were highly sensitive to ABT-737, a cell- ... prior lines of therapy (LOT), 13% had t(11;14) positive and 79% were BCL2-high expressers by ... 2019, when specifically examined for patients with t(11;14), the median PFS had not been reached for ... utilized this profiling and the presence of t(11;14) to inform the treatment of patients with venetoclax. ...
Tópico(s): Cancer Mechanisms and Therapy
2020 - Wiley | American Journal of Hematology
... in part a reprint (1864), no.1-4, 11-14 having been reprinted. The t.-p. bears the ...
0000 - Gale Group | Sabin
Wen Gao, Juan Du, Junru Liu, Huixing Zhou, Zhiyao Zhang, Yuan Jian, Guangzhong Yang, Guorong Wang, Ying Tian, Yanchen Li, Yin Wu, Weijun Fu, Juan Li, Wenming Chen,
To investigate the prognostic value of t(11;14) for de novo multiple myeloma (MM) patients in novel agent era.A total of 455 patients with fluorescence in situ hybridization (FISH), before ... without HR cytogenetics, 55 were in the t(11;14) group, and 248 were in the standard risk (SR) group without t(11;14). Gain in 1q21 was observed in 38.9% patients with t(11;14). There were no differences in median progression free ... survival (OS), respectively, between patients in the t(11;14) group and those in the SR group. Patients ...
Tópico(s): Peptidase Inhibition and Analysis
2020 - Frontiers Media | Frontiers in Oncology
... in part a reprint (1864), no.1-4, 11-14 having been reprinted. The t.-p. bears the ...
0000 - Gale Group | Sabin
Talha Badar, Parameswaran Hari, Omar Dávila, Raphael Fraser, Baldeep Wirk, Binod Dhakal, César O. Freytes, Cesar Rodriguez Valdes, Cindy Lee, David H. Vesole, Ehsan Malek, Gerhard Hildebrandt, Heather Landau, Hemant S. Murthy, Hillard M. Lazarus, Jesús G. Berdeja, Kenneth R. Meehan, Melhem Solh, Miguel Ángel Díaz, Mohamed A. Kharfan‐Dabaja, Natalie S. Callander, Nosha Farhadfar, Qaiser Bashir, Rammurti T. Kamble, Ravi Vij, Reinhold Munker, Robert A. Kyle, Saurabh Chhabra, Shahrukh K. Hashmi, Siddhartha Ganguly, Sundar Jagannath, Taiga Nishihori, Yago Nieto, Shaji Kumar, Nina Shah, Anita D’Souza,
Multiple myeloma (MM) with the translocation t(11;14) may have inferior outcomes in comparison with other standard-risk MM, and it has been suggested to portend a worse prognosis in African ... CIBMTR) database to examine the impact of t(11;14) on the clinical outcomes of patients with MM ... analyzed in 4 groups: African Americans with t(11;14) (n = 117), African Americans without t(11;14) (n = 968), Whites with t(11;14) (n = 266), and Whites without t(11;14) (n = 2187).African Americans with t(11;14) were younger, had lower Karnofsky scores, and had ...
Tópico(s): Protein Degradation and Inhibitors
2020 - Wiley | Cancer
... in part a reprint (1864), no.1-4, 11-14 having been reprinted. The t.-p. bears the ...
0000 - Gale Group | Sabin
Brett Dumas, Hassan Yameen, Shayna Sarosiek, J. Mark Sloan, Vaishali Sanchorawala,
... and stem cell transplantation. The presence of t(11;14), seen in up to 40-60% of patients ... 2 inhibition with venetoclax in patients with t(11;14) in multiple myeloma. We report on 135 patients ... compared between a cohort of patients with t(11;14) and those without the translocation. Forty-four patients had the presence of t(11;14). Five-year overall survival was 46% for those with t(11;14) and 72% in patients without this translocation (p = . ... survival was 17 months for patients with t(11;14) compared to 34 months without (p = .068). Haematologic ...
Tópico(s): Chronic Myeloid Leukemia Treatments
2020 - Taylor & Francis | Amyloid
... in part a reprint (1864), no.1-4, 11-14 having been reprinted. The t.-p. bears the ...
0000 - Gale Group | Sabin
Charlotte Gran, Katarina Uttervall, Johanna Borg Bruchfeld, Ann Wallblom, Evren Alici, Gösta Gahrton, Hareth Nahi,
... common translocation in multiple myeloma (MM) is t(11;14)(q13;q32), and its importance as prognostic factor ... newly diagnosed myeloma patients, outcomes in patients with (11;14) and standard risk (t(11;14)SR) or high risk (t(11;14)HR) cytogenetics were compared to outcomes of patients without t(11;14) and SR (non-t(11;14)SR) or HR (non-t(11;14)HR), respectively.Overall progression-free survival (PFS) was shorter in t(11;14)SR than non-t(11;14)SR (median 28.9 vs 35.3 months); ...
Tópico(s): PI3K/AKT/mTOR signaling in cancer
2019 - Wiley | European Journal Of Haematology
... Nouveaux Exercises e Mathématique (Exercises de Prague)--T. 11-14. Exercices D'analyse et de Physique Mathématique... [2. ...
1889 - Gale Group | NCCO SciTechMed 2 of 2
Produção Nacional
Revisado por pares
Simon J. Harrison, Michèle Cavo, Javier de la Rubia, Rakesh Popat, Cristina Gasparetto, Vânia Hungria, Hans Salwender, Kenshi Suzuki, Inho Kim, Philippe Moreau, Andrew Spencer, Michael O’Dwyer, Mamta Garg, Elizabeth A. Punnoose, Muhammad Jalaluddin, Jia Jia, Xiaoqing Yang, Yan Sun, James E. Ward, Paulo Maciag, Jeremy A. Ross, Shaji Kumar,
... encouraging clinical efficacy of Ven + d in t(11;14) MM and in a broader patient (pt) population ... BCL-2 IHC High, p=0.0021). t(11;14) MM had the highest levels of BCL-2 ... DCt 0.406 vs 0.212 in t(11;14) negative, p=0.0132), however high BCL-2 expression was not limited to the t(11;14) subgroup. Univariate analyses showed higher BCL2 expression in ... subgroups with the greatest PFS improvement were t(11;14) (HR=0.10; 95% CI: 0.02-0. ... lt;0.001; Table 1). Since the t(11;14) and High BCL2 patient populations do not completely ...
Tópico(s): Cancer Mechanisms and Therapy
2019 - Elsevier BV | Blood